Tute Genomics Acquired By PierianDx

“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare.”

All of these actions have led us to today. St. Louis-based PierianDx, also a company greatly invested in bringing personalized medicine to the masses, has acquired Tute Genomics.

“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare,” Reid Robison, CEO of Tute, said in a statement.

As part of the transaction, a few things will happen. The most obvious: both platforms will begin to combine, with spring of 2017 the hopeful timeframe for full integration. Robison will join the PierianDx Board of Directors, while PierianDx will continue to maintain a development team in Provo. Last but not least, two Tute higher-ups — COO Andy Olson and VP of Product Development Bryce Daines — will relocate to St. Louis and presumably celebrate like prominent St. Louis citizens are known to do.